Who are powder BoNT-A (BOTOX/Vistabel)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Botulinum Toxin Type A 900kDa, Onabotulinumtoxin A (BoNT), Botulinum Toxin Type A (Botox), Botox infiltration, Radiesse, Xeomin, Belotero, Placebo / Botulinum Toxin A.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/powder-bont-a-botox-vistabel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

powder BoNT-A (BOTOX/Vistabel) — Competitive Intelligence Brief

powder BoNT-A (BOTOX/Vistabel) (powder BoNT-A (BOTOX/Vistabel)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neurotoxin; botulinum toxin type A. Area: Dermatology; Neurology; Aesthetics.

marketed Neurotoxin; botulinum toxin type A SNAP-25 (synaptosome-associated protein of 25 kDa) Dermatology; Neurology; Aesthetics Biologic Live · refreshed every 30 min

Target snapshot

powder BoNT-A (BOTOX/Vistabel) (powder BoNT-A (BOTOX/Vistabel)) — Galderma R&D. Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
powder BoNT-A (BOTOX/Vistabel) TARGET	powder BoNT-A (BOTOX/Vistabel)	Galderma R&D	marketed	Neurotoxin; botulinum toxin type A	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botulinum Toxin Type A 900kDa	Botulinum Toxin Type A 900kDa	Allergan	marketed	Neurotoxin; acetylcholine release inhibitor	SNAP-25 (synaptosome-associated protein of 25 kDa)
Onabotulinumtoxin A (BoNT)	Onabotulinumtoxin A (BoNT)	Edgar LeClaire, MD	marketed	Neurotoxin; botulinum toxin serotype A	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botulinum Toxin Type A (Botox)	Botulinum Toxin Type A (Botox)	University of Utah	marketed	Neurotoxin; neuromuscular blocking agent	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botox infiltration	Botox infiltration	University Rovira i Virgili	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosome-associated protein); acetylcholine release machinery
Radiesse, Xeomin, Belotero	Radiesse, Xeomin, Belotero	Main Line Center for Laser Surgery	marketed	Dermal fillers and neurotoxin
Placebo / Botulinum Toxin A	Placebo / Botulinum Toxin A	Walter Reed Army Medical Center	marketed	Neurotoxin / Acetylcholine release inhibitor	SNAP-25 (synaptosome-associated protein of 25 kDa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neurotoxin; botulinum toxin type A class)

Galderma R&D · 1 drug in this class
The Methodist Hospital Research Institute · 1 drug in this class
University Hospital, Clermont-Ferrand · 1 drug in this class
University Rovira i Virgili · 1 drug in this class
Women and Infants Hospital of Rhode Island · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). powder BoNT-A (BOTOX/Vistabel) — Competitive Intelligence Brief. https://druglandscape.com/ci/powder-bont-a-botox-vistabel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab